Overview
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Eligibility
Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form.
- 18-75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
- Life expectancy ≥ 12 weeks.
Exclusion Criteria:
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.